Forest Laboratories reported that a late-stage trial of milnacipran as a treatment for fibromyalgia failed to hit the primary endpoint. But Forest and its development partner, Cypress Bioscience, said that the results warranted continued investigation of the drug in an ongoing Phase III trial and another late-stage study that would soon be initiated. Researchers said the drug was generally well tolerated with most patient withdrawals coming early in the study.
- read this press release for more information